A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 23 Dec 2017
At a glance
- Drugs EFT 508 (Primary)
- Indications Haematological malignancies; Lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Effector Therapeutics
- 12 Dec 2017 Preliminary results (n=6) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 11 Dec 2017 Results published in an Effector Therapeutics media release.
- 05 Jun 2017 According to an Effector Therapeutics media release, initial phase II efficacy data is anticipated in 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History